Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
Overview of MaxCyte (MXCT)
MaxCyte, Inc. is a pioneering commercial cell engineering company that plays a critical role in advancing the development of next-generation cell-based therapies. The company specializes in providing enabling platform technologies that support the discovery, development, and commercialization of innovative therapeutic solutions. MaxCyte’s proprietary Flow Electroporation® technology and its ExPERT™ platform are at the heart of its operations, offering unparalleled precision, scalability, and efficiency in the engineering of a wide variety of cell types. These technologies are designed to meet the rigorous demands of the rapidly expanding cell and gene therapy market.
Core Business Model
MaxCyte generates revenue through a diversified business model that includes the sale and licensing of its proprietary instruments, as well as the supply of single-use disposable processing assemblies. The company’s ExPERT™ platform, which includes a suite of instruments (ATx™, STx™, GTx™, and VLx™), is complemented by software protocols and a robust intellectual property portfolio. This combination enables MaxCyte to serve a broad spectrum of applications, from early-stage research to clinical development and commercialization of cell-based therapies.
Industry Context and Market Position
Operating within the high-growth cell and gene therapy sector, MaxCyte addresses critical challenges in cell engineering, such as achieving high transfection efficiency, maintaining cell viability, and ensuring seamless scalability. The company’s platforms are integral to the workflows of biopharmaceutical companies, academic institutions, and research organizations. MaxCyte has established over 25 clinical and commercial partnerships, underscoring its significance as a trusted partner in the industry. These collaborations often include licensing agreements that provide recurring revenue streams through milestone payments and sales-based royalties.
Technology and Differentiation
The cornerstone of MaxCyte’s technological offering is its clinically validated Flow Electroporation® technology, which enables the non-viral delivery of molecules into cells with high efficiency and minimal toxicity. This technology is particularly valuable for applications in CAR-T cell therapies, gene editing, and other cutting-edge therapeutic modalities. The ExPERT™ platform further differentiates MaxCyte by offering a scalable solution that can be seamlessly integrated across various stages of therapeutic development, from discovery to commercialization.
Value Proposition
MaxCyte’s value proposition lies in its ability to empower its partners to overcome complex cell engineering challenges. By providing not only advanced technology but also comprehensive scientific, technical, and regulatory support, MaxCyte enables its clients to accelerate the development of transformative therapies. This holistic approach positions the company as a critical enabler in the cell and gene therapy ecosystem, helping to unlock the full potential of cell-based medicines to address unmet medical needs.
Competitive Landscape
In a competitive market that includes other providers of cell engineering and gene therapy technologies, MaxCyte distinguishes itself through its proven track record, robust intellectual property portfolio, and the versatility of its platforms. Its ability to support both ex vivo and in vivo applications further enhances its appeal to a diverse range of clients. The company’s focus on enabling high-performance, scalable, and safe cell engineering solutions ensures its relevance in a rapidly evolving industry.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading cell-engineering focused company, has announced it will release its third quarter 2024 financial results after the U.S. market close on Wednesday, November 6th, 2024. The company, which provides enabling platform technologies for cell therapeutics and bioprocessing applications, will host a conference call to discuss the financial results at 4:30 p.m. Eastern Time on the same day.
Investors interested in participating in the earnings conference call are required to register online, with registration recommended at least a day in advance. A live and archived webcast of the event will be available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Ali Soleymannezhad as Chief Commercial Officer, effective September 11, 2024. In his new role, Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform and expand the company's market impact in Cell and Gene Therapy. Previously, he served as Executive Vice President of Bioprocessing at MaxCyte, leading global product development and marketing strategy for the bioprocessing business.
Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to joining MaxCyte, he held executive positions at Tosoh Bioscience, including Executive Vice President for the Separations and Purification business, overseeing a team of 140 employees across four global sites. MaxCyte's CEO, Maher Masoud, expressed confidence in Soleymannezhad's ability to drive future growth for the company.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenue.
Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.
MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering and platform technologies for cell-based therapeutics and bioprocessing applications, has announced its participation in the Virtual Craig-Hallum Capital Group Bioprocessing Conference. The event is scheduled for Thursday, September 19th at 9:30 am ET.
Company management will be presenting at the conference, providing insights into MaxCyte's innovative technologies and market position. For those unable to attend live, a replay of the event will be made available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
This participation underscores MaxCyte's commitment to engaging with the investment community and showcasing its advancements in cell engineering and bioprocessing technologies.
MaxCyte (NASDAQ: MXCT) reported Q2 2024 financial results and updated full-year guidance. Total revenue reached $10.4 million, up 15% year-over-year. Core business revenue declined 9% to $7.6 million, while SPL Program-related revenue surged 279% to $2.9 million. The company signed five new SPL clients year-to-date, bringing the total to 28. MaxCyte affirmed its 2024 core business revenue guidance of flat to 5% growth and increased SPL Program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering platform technologies, will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes. The company invites investors to join a conference call at 4:30 p.m. Eastern Time, where management will discuss these results. Interested participants should register online in advance. A live and archived webcast of the call will be available on the MaxCyte website.
MaxCyte, a leader in cell-engineering technologies, announced its participation in the William Blair 44th Annual Growth Stock Conference. The event is scheduled for June 5th at 2:40 pm CT. The session will be available live and archived on MaxCyte's investor relations website. MaxCyte focuses on advancing cell-based therapeutics and bioprocessing applications, emphasizing discovery, development, and commercialization.
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive annual licensing fees, clinical development milestones, and royalties on net sales of the licensed products. This marks MaxCyte’s 28th clinical/commercial partnership, emphasizing its role in advancing cell-based therapeutics.
The partnership aims to enhance Legend Biotech’s non-viral engineered therapeutic pipeline, leveraging MaxCyte’s expertise in scalable cell engineering and regulatory support. The ExPERT™ platform provides high transfection efficiency and seamless scalability, essential for developing innovative cell therapies. Both companies aim to transform the treatment landscape and meet expanding clinical and commercial needs.
MaxCyte, Inc. reported a total revenue of $11.3 million in the first quarter of 2024, marking a 32% increase year-over-year. Core business revenue grew by 5% to $8.2 million. The company signed four Strategic Platform License (SPL) clients year-to-date, with a total of 27 partners. Cash, cash equivalents, and investments stood at $202.5 million as of March 31, 2024. MaxCyte affirmed its 2024 revenue guidance, expecting flat to 5% growth in core business revenue and approximately $5 million in SPL Program-related revenue.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
What does MaxCyte do?
How does MaxCyte generate revenue?
What is Flow Electroporation® technology?
Who are MaxCyte's clients?
What is the ExPERT™ platform?
What industries does MaxCyte operate in?
How does MaxCyte differentiate itself from competitors?
What are some applications of MaxCyte's technology?
What is the significance of MaxCyte’s clinical partnerships?
What challenges does MaxCyte address in cell engineering?
